The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Blood Cancer Therapeutics Market Research Report 2025
Synopsis
Blood cancer is an umbrella term for cancers that affect the blood, bone marrow and lymphatic system.
The global Blood Cancer Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Blood Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Therapeutics.
Report Scope
The Blood Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Roche
Novartis
Boehringer Ingelheim
Pfizer
Sanofi
Segment by Type
Chronic Myeloid Leukemia (CML)
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Segment by Application
Cancer Research Centers
Cancer Hospital
Surgical Centers
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Blood cancer is an umbrella term for cancers that affect the blood, bone marrow and lymphatic system.
The global Blood Cancer Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Blood Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Therapeutics.
Report Scope
The Blood Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Blood Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Roche
Novartis
Boehringer Ingelheim
Pfizer
Sanofi
Segment by Type
Chronic Myeloid Leukemia (CML)
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Segment by Application
Cancer Research Centers
Cancer Hospital
Surgical Centers
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chronic Myeloid Leukemia (CML)
1.2.3 Acute Lymphocytic Leukemia (ALL)
1.2.4 Chronic Lymphocytic Leukemia (CLL)
1.2.5 Acute Myeloid Leukemia (AML)
1.3 Market by Application
1.3.1 Global Blood Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer Research Centers
1.3.3 Cancer Hospital
1.3.4 Surgical Centers
1.3.5 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Cancer Therapeutics Market Perspective (2019-2030)
2.2 Blood Cancer Therapeutics Growth Trends by Region
2.2.1 Global Blood Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Blood Cancer Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Blood Cancer Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Blood Cancer Therapeutics Market Dynamics
2.3.1 Blood Cancer Therapeutics Industry Trends
2.3.2 Blood Cancer Therapeutics Market Drivers
2.3.3 Blood Cancer Therapeutics Market Challenges
2.3.4 Blood Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Cancer Therapeutics Players by Revenue
3.1.1 Global Top Blood Cancer Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Blood Cancer Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Blood Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Cancer Therapeutics Revenue
3.4 Global Blood Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Blood Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Therapeutics Revenue in 2023
3.5 Blood Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Blood Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Blood Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Cancer Therapeutics Breakdown Data by Type
4.1 Global Blood Cancer Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Blood Cancer Therapeutics Forecasted Market Size by Type (2025-2030)
5 Blood Cancer Therapeutics Breakdown Data by Application
5.1 Global Blood Cancer Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Blood Cancer Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Blood Cancer Therapeutics Market Size (2019-2030)
6.2 North America Blood Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Blood Cancer Therapeutics Market Size by Country (2019-2024)
6.4 North America Blood Cancer Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Cancer Therapeutics Market Size (2019-2030)
7.2 Europe Blood Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Blood Cancer Therapeutics Market Size by Country (2019-2024)
7.4 Europe Blood Cancer Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Blood Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Blood Cancer Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Blood Cancer Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Cancer Therapeutics Market Size (2019-2030)
9.2 Latin America Blood Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Blood Cancer Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Blood Cancer Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Blood Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Blood Cancer Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Blood Cancer Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Blood Cancer Therapeutics Introduction
11.1.4 AbbVie Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Blood Cancer Therapeutics Introduction
11.2.4 AstraZeneca Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.2.5 AstraZeneca Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Blood Cancer Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Blood Cancer Therapeutics Introduction
11.4.4 GlaxoSmithKline Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Blood Cancer Therapeutics Introduction
11.5.4 Roche Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Blood Cancer Therapeutics Introduction
11.6.4 Novartis Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Detail
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Blood Cancer Therapeutics Introduction
11.7.4 Boehringer Ingelheim Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.7.5 Boehringer Ingelheim Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Blood Cancer Therapeutics Introduction
11.8.4 Pfizer Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Blood Cancer Therapeutics Introduction
11.9.4 Sanofi Revenue in Blood Cancer Therapeutics Business (2019-2024)
11.9.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Blood Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Chronic Myeloid Leukemia (CML)
Table 3. Key Players of Acute Lymphocytic Leukemia (ALL)
Table 4. Key Players of Chronic Lymphocytic Leukemia (CLL)
Table 5. Key Players of Acute Myeloid Leukemia (AML)
Table 6. Global Blood Cancer Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Blood Cancer Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Blood Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Blood Cancer Therapeutics Market Share by Region (2019-2024)
Table 10. Global Blood Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Blood Cancer Therapeutics Market Share by Region (2025-2030)
Table 12. Blood Cancer Therapeutics Market Trends
Table 13. Blood Cancer Therapeutics Market Drivers
Table 14. Blood Cancer Therapeutics Market Challenges
Table 15. Blood Cancer Therapeutics Market Restraints
Table 16. Global Blood Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Blood Cancer Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Blood Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Therapeutics as of 2023)
Table 19. Ranking of Global Top Blood Cancer Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Blood Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Blood Cancer Therapeutics Product Solution and Service
Table 23. Date of Enter into Blood Cancer Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Blood Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Blood Cancer Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Blood Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Blood Cancer Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Blood Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Blood Cancer Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Blood Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Blood Cancer Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Blood Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Blood Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Blood Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Blood Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Blood Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Blood Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Blood Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Blood Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Blood Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Blood Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Blood Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Blood Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Blood Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Blood Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Blood Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Detail
Table 49. AbbVie Business Overview
Table 50. AbbVie Blood Cancer Therapeutics Product
Table 51. AbbVie Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. AstraZeneca Company Detail
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Blood Cancer Therapeutics Product
Table 56. AstraZeneca Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Bristol-Myers Squibb Company Detail
Table 59. Bristol-Myers Squibb Business Overview
Table 60. Bristol-Myers Squibb Blood Cancer Therapeutics Product
Table 61. Bristol-Myers Squibb Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Bristol-Myers Squibb Recent Development
Table 63. GlaxoSmithKline Company Detail
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Blood Cancer Therapeutics Product
Table 66. GlaxoSmithKline Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 67. GlaxoSmithKline Recent Development
Table 68. Roche Company Detail
Table 69. Roche Business Overview
Table 70. Roche Blood Cancer Therapeutics Product
Table 71. Roche Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Novartis Company Detail
Table 74. Novartis Business Overview
Table 75. Novartis Blood Cancer Therapeutics Product
Table 76. Novartis Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 77. Novartis Recent Development
Table 78. Boehringer Ingelheim Company Detail
Table 79. Boehringer Ingelheim Business Overview
Table 80. Boehringer Ingelheim Blood Cancer Therapeutics Product
Table 81. Boehringer Ingelheim Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Boehringer Ingelheim Recent Development
Table 83. Pfizer Company Detail
Table 84. Pfizer Business Overview
Table 85. Pfizer Blood Cancer Therapeutics Product
Table 86. Pfizer Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Pfizer Recent Development
Table 88. Sanofi Company Detail
Table 89. Sanofi Business Overview
Table 90. Sanofi Blood Cancer Therapeutics Product
Table 91. Sanofi Revenue in Blood Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Sanofi Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Blood Cancer Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Blood Cancer Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Chronic Myeloid Leukemia (CML) Features
Figure 4. Acute Lymphocytic Leukemia (ALL) Features
Figure 5. Chronic Lymphocytic Leukemia (CLL) Features
Figure 6. Acute Myeloid Leukemia (AML) Features
Figure 7. Global Blood Cancer Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Blood Cancer Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Cancer Research Centers Case Studies
Figure 10. Cancer Hospital Case Studies
Figure 11. Surgical Centers Case Studies
Figure 12. Clinics Case Studies
Figure 13. Blood Cancer Therapeutics Report Years Considered
Figure 14. Global Blood Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Blood Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Blood Cancer Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Blood Cancer Therapeutics Market Share by Players in 2023
Figure 18. Global Top Blood Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Blood Cancer Therapeutics Revenue in 2023
Figure 20. North America Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Blood Cancer Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Blood Cancer Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Blood Cancer Therapeutics Market Share by Region (2019-2030)
Figure 34. China Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Blood Cancer Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Blood Cancer Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Blood Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. AbbVie Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 49. AstraZeneca Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 52. Roche Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 54. Boehringer Ingelheim Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 56. Sanofi Revenue Growth Rate in Blood Cancer Therapeutics Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
